Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Oct;44(10):2329-2336.
doi: 10.2337/dc21-0226. Epub 2021 Aug 6.

Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts

Collaborators, Affiliations
Clinical Trial

Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts

Michael G Voss et al. Diabetes Care. 2021 Oct.

Abstract

Objective: To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes.

Research design and methods: We examined 2-h OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (mean ± SD age, 13.84 ± 9.53 years; BMI Z-score, 0.33 ± 1.07; 56.1% male) and 3,720 PTP participants (age, 16.01 ± 12.33 years; BMI Z-score, 0.66 ± 1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-score, HOMA-insulin resistance, and peak glucose/C-peptide levels, respectively) were performed.

Results: In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose >30 min and time to peak C-peptide >60 min (P < 0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: χ2 = 25.76 vs. χ2 = 8.62; PTP: χ2 = 149.19 vs. χ2 = 79.98; all P < 0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time.

Conclusions: In two independent at-risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence curves for type 1 diabetes in DPT-1 and PTP, based on time to peak glucose (A and B) or peak C-peptide (C and D) levels during 2-h OGTTs (P < 0.001 for all). Dashed lines indicate peak glucose after 30 min (A and B) or peak C-peptide after 60 min (C and D). Solid lines indicate peak glucose at 30 min (A and B) or peak C-peptide at 60 min (C and D). TN, TrialNet.

References

    1. Sosenko JM, Palmer JP, Greenbaum CJ, et al. . Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643–649 - PubMed
    1. Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991;34:93–102 - PubMed
    1. Chase HP, Voss MA, Butler-Simon N, Hoops S, O’Brien D, Dobersen MJ. Diagnosis of pre-type I diabetes. J Pediatr 1987;111:807–812 - PubMed
    1. Srikanta S, Ganda OP, Rabizadeh A, Soeldner JS, Eisenbarth GS. First-degree relatives of patients with type I diabetes mellitus—islet-cell antibodies and abnormal insulin secretion. N Engl J Med 1985;313:461–464 - PubMed
    1. Knip M, Vähäsalo P, Karjalainen J, Lounamaa R; Childhood Diabetes in Finland Study Group . Natural history of preclinical IDDM in high risk siblings. Diabetologia 1994;37:388–393 - PubMed

Publication types